Antimicrobial agents and chemotherapy · 2025
Construction and assessment of a predictive framework for Enterobacterales bloodstream infection in real-world adult onco-hematology patients using Lasso-Cox regression.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cui Yuqing, Feng Xiaomeng, Wang Jieru, Liu Li, Zhang Lining, Lin Qingsong, Pan Ling, Zhen Sisi, Fan Yuping, Chen Xin, Zhang Tingting, Mi Yingchang, Xiao Zhijian, Jiang Erlie, Han Mingzhe, Wang Jianxiang, Feng Sizhou
Аннотация
Bloodstream infections (BSIs) caused by Enterobacterales, particularly Escherichia coli (EC) and Klebsiella pneumoniae (KP), are the most prevalent infectious issues in individuals with hematologic malignancies (HM). Prognostic tools integrating pathogen-specific risks are urgently needed to optimize early clinical decision-making. This retrospective cohort study analyzed 1,299 HM patients with EC- or KP-BSI (2017-2023). Patients were randomly allocated to training (n = 909) and validation (n = 390) cohorts. Prognostic variables were selected through Lasso regression, followed by Cox proportional hazards modeling to construct a 30-day mortality prediction nomogram. Model performance was rigorously validated using receiver operating characteristic curves (AUCs), calibration curves, and decision-curve analysis. The cohort comprised 653 EC-BSI and 646 KP-BSI cases, predominantly with acute myeloid leukemia (54.3%). Pulmonary/skin-soft tissue infection origins, hematopoietic stem cell transplantation, concurrent septic shock/pneumonia, hypoproteinemia, prolonged neutropenia before BSI, and carbapenem-resistant strains emerged as independent predictors of mortality. Conversely, tumor consolidation stage status and ceftazidime-avibactam-containing regimens were predictive of survival benefit. The model demonstrated high predictive accuracy (AUC 0.881), excellent calibration, and superior clinical utility. We developed a simple model using routine clinical parameters that predicts 30-day mortality in HM patients with EC- or KP-BSI, guiding therapy without complex biomarkers.